NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only
 

A new enzyme immunoassay for titration of antibodies to a cross-reactive epitope of the major core protein of HIV1 and HIV2: diagnosis and prognosis usefulness.

Janvier B, Barin F, Mandrand B; International Conference on AIDS.

Int Conf AIDS. 1990 Jun 20-23; 6: 126 (abstract no. F.A.209).

URA-CNRS 1334, 37044 Tours, France

OBJECTIVE: To study the immune response towards a cross-reactive epitope of p24/HIV1 and p26/HIV2 proteins in sera of HIV1 or HIV2 infected patients. A sequential inhibition assay (SIEIA) was developed using a murine monoclonal antibody, 23A5G4, recognizing the linear epitope AAEWDRVHP (a.a. 209 to 217 of p55/HIV1). MATERIALS: Anti-p24 titration was done on HIV1 sera from France and Central Africa, "anti-p24 only" sera. Anti-p26 titration was done on HIV2 sera. Positive sera were chosen at different clinical stages of the disease. METHODS: Solid phase of SIEIA was composed of HIV1/HTLV3B or HIV2/TY viruses captured on rabbit polyclonal IgG to p24/HIV1 or p26/HIV2. Samples were incubated 15' at 37 degrees C before to add the peroxydase monoclonal anti-p24 conjugate for 90' at 37 degrees C. A standard curve was done in every run to compare antibody titers. RESULTS: Percent inhibition and antibody titer were calculated for each sample. Results obtained confirm the anti-p24 decline in sera of European patients developing AIDS. Whereas 79% of CDC II patients were positive in anti-p24, 48% of CDC III were positive and only 27% of CDC IV were positive. Results were different in African patients since 82% of CDC IV patients were anti-p24 positive. None of the "anti-p24 only" reactive sera was positive in our SIEIA. Most of the sera collected at the early phase of HIV1 and HIV2 seroconversions were positive in the SIEIA, indicating that AAEWDRVHP epitope is recognized early in infection. CONCLUSION: Both monoclonal antibody 23A5G4 and the corresponding epitope AAEWDRVHP are interesting diagnosis and prognosis tools in both HIV1 and HIV2 infection.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Africa, Central
  • Animals
  • Antibodies
  • Epitopes
  • France
  • HIV Antibodies
  • HIV-1
  • HIV-2
  • Humans
  • Immunoenzyme Techniques
  • Indicators and Reagents
  • Prognosis
  • Rabbits
  • Viral Core Proteins
  • diagnosis
  • immunology
Other ID:
  • 20020990
UI: 102184104

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov